Krebs Biochemicals & Industries Ltd (KREBSBIO)
🎯 Key Takeaways
- Krebs Biochemicals & Industries Ltd is undergoing a strategic transformation through its planned amalgamation with Ipca Laboratories, marking a pivotal shift from standalone operations to integration within a larger pharmaceutical entity. The company, historically marked by persistent losses and negative cash flows, is now executing a structural realignment aimed at securing supply chain resilience and operational efficiency, though near-term financial performance remains weak.
- Revenue grew 2.5% QoQ to ₹7 in Q1FY27.
- ⚠️ 1) The company's standalone operations are financially fragile, with persistent losses, negative cash flows, and a deteriorating balance sheet, raisin
- Market Cap
- ₹127
- P/B Ratio
- -0.78
- ROE
- 8.7%
- ROCE
- -10.9%
- Debt/Equity
- -1.38
- Promoter
- 72.7%
📖 The Story
Krebs Biochemicals & Industries Ltd is undergoing a strategic transformation through its planned amalgamation with Ipca Laboratories, marking a pivotal shift from standalone operations to integration within a larger pharmaceutical entity. The company, historically marked by persistent losses and negative cash flows, is now executing a structural realignment aimed at securing supply chain resilience and operational efficiency, though near-term financial performance remains weak.
📰 What's Happening
The most significant development is the board-approved amalgamation with Ipca Laboratories, effective April 1, 2026, under which Krebs will merge without cash consideration, issuing shares at a ratio of 1 share for every 200 held. This move, detailed in filings from June 26, 2026, is intended to consolidate operations, secure critical API supply chains, and eliminate administrative redundancies. Additionally, a board meeting on June 22, 2026, confirmed the unaudited Q1 FY26 results, which reflect ongoing operational challenges with minimal revenue and negative profitability. The company also disclosed a regulatory filing under SEBI Takeover Regulations on April 9, 2026, signaling a potential change in control, though specific financial implications remain unspecified.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 4 | 7 | 7 | 7 |
| Operating Profit | -4 | -1 | -2 | -1 |
| OPM % | -106.0% | -18.4% | -35.7% | -10.9% |
| Net Profit | -6 | -3 | -2 | -2 |
| EPS | ₹-2.85 | ₹-1.45 | ₹-1.09 | ₹-1.15 |
The company continues to operate at a significant loss, with Q1 FY26 (June 2026) showing revenue of just ₹7 crores and an operating profit of -₹1 crore, reflecting a -10.9% margin. This follows a sequential improvement in operating loss narrowing from -₹4 crores in September 2025 to -₹1 crore in June 2026, suggesting some stabilization in core operations despite the scale. However, net loss remains elevated at -₹2 crores, and EPS stands at -₹1.15, indicating limited progress toward profitability. The financial trend underscores that the business has not yet achieved operational break-even, though the rate of loss contraction has improved in the most recent quarter.
🔮 Management Outlook & What's Next
Management has not provided explicit forward guidance on revenue growth or profitability in the available filings, but the merger with Ipca is framed as a strategic step to enhance long-term resilience and supply chain control. The integration is expected to leverage Ipca’s scale and operational frameworks, though near-term financial contributions from Krebs remain marginal given its standalone revenue base of ₹7 crores in Q1 FY26. The company’s focus appears to be on structural consolidation rather than near-term performance metrics.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2026 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 |
| Reserves | -168 | -184 | -182 | -179 |
| Borrowings | 212 | 225 | 221 | 219 |
| Total Liabilities | 169 | 163 | 166 | 168 |
| Fixed Assets | 148 | 141 | 142 | 144 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 169 | 163 | 166 | 168 |
The balance sheet reveals a highly leveraged structure with total borrowings of ₹225 crores against a negative equity position of ₹162 crores (after accounting for reserves of -₹184 crores) as of March 2026. Total assets have declined slightly to ₹163 crores, indicating asset erosion or reclassification, while liabilities remain dominant. This suggests aggressive capital deployment or deficit financing, though the lack of retained earnings or positive reserves raises concerns about financial sustainability without external support or integration benefits post-merger.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating | -8 | -2 |
| Investing | -5 | -4 |
| Financing | +13 | +6 |
| Net Cash Flow | +0 | -0 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 72.7% | 72.7% | 72.7% | 72.7% |
| FII | 0.5% | 0.5% | 0.5% | 0.5% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 19.7% | 19.8% | 19.8% | 19.7% |
| # Shareholders | 8,912 | 8,710 | 8,553 | 8,521 |
Promoter holding remains stable at 72.74% across all recent quarters, indicating no dilution or stake sale activity. Institutional investor interest is negligible, with FII and DII holdings collectively below 1% and showing no upward trend. The shareholder base is highly concentrated among promoters and a large number of small public shareholders (8,500+), but there is no evidence of foreign or domestic institutional accumulation. The lack of institutional interest may reflect skepticism about near-term value creation.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.46 L Cr | 36.9 | 18.7% | — | 0.05 |
| DIVISLAB | 2.52 L Cr | 86.0 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.87 L Cr | 78.4 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.19 L Cr | 26.6 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.1 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 98.0 | 20.8% | — | 0.45 |
| MANKIND | 1.05 L Cr | 51.4 | 13.9% | — | 0.38 |
| DRREDDY | 1.04 L Cr | 32.3 | 10.1% | — | 0.17 |
| AUROPHARMA | 97,987 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,190 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) The company's standalone operations are financially fragile, with persistent losses, negative cash flows, and a deteriorating balance sheet, raising concerns about viability without the merger's benefits. 2) The amalgamation with Ipca remains subject to regulatory and shareholder approvals, introducing execution risk, particularly given the lack of detailed financial impact disclosure. 3) Integration risk is heightened as Krebs will cease to operate independently, and its standalone financials may not reflect the post-merger reality, making valuation and recovery prospects uncertain.
📋 Recent Filings
- 🟡 Board Meeting2026-09-29Krebs Biochemicals & Industries held its 34th AGM on September 29, 2026 via video conference, approving the audited financials for FY2026, reappointin…
- 🟡 voting results2026-09-29Krebs Biochemicals & Industries Limited announced voting results from its September 29, 2026 AGM, confirming all five proposed resolutions passed with…
- Announcement2026-09-21Krebs Biochemicals & Industries Ltd announced that its trading window will close on September 30, 2026, ahead of the unaudited Q2 results announcement…
- 🟡 Board Meeting2026-09-04Krebs Biochemicals & Industries Limited announced its 34th Annual General Meeting (AGM) to be held on 29 September 2026 at 11:30 a.m. via video confer…
- 🔴 annual report2026-09-04Krebs Biochemicals & Industries Limited reported a consolidated net loss of ₹1,693.31 Lakhs for FY 2025-26, narrowing from ₹2,693.93 Lakhs loss in FY …
- 🟡 Board Meeting2026-08-06The board approved unaudited Q1 FY26 results and a limited auditor review, confirming financials for the quarter ended June 30, 2026, after a meeting …
- share transfer2026-07-02Krebs Biochemicals & Industries Limited received SEBI-mandated certificates from its share transfer agent KFIN Technologies for the quarter ended June…
- 🔴 Corporate Action2026-06-26Krebs Biochemicals announced a scheme of amalgamation with Ipca Laboratories effective April 1, 2026, where the company will merge into Ipca without c…
- 🟡 Board Meeting2026-06-26Krebs Biochemicals announced board approval of its amalgamation with Ipca Laboratories under Sections 230-232 of the Companies Act, subject to regulat…
- Financial Results2026-06-22Krebs Biochemicals & Industries Limited announced that its trading window will close on June 30, 2026, ahead of the unaudited Q1 2026 financial result…
🧠 Analyst's Read
Krebs Biochemicals is in a transitional phase defined by strategic realignment rather than financial recovery, with its future prospects closely tied to the successful integration with Ipca Laboratories. Investors should monitor regulatory clearances for the merger, post-merger performance within the combined entity, and any disclosure of standalone financial wind-down or transition costs. The current financial profile reflects a distressed profile, but the merger may provide long-term stability if successfully executed.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-30.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when KREBSBIO files new disclosures
Track KREBSBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track KREBSBIO — FreeFree account · 2 AI queries/day